A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

This study is testing a new drug called HRS-4642 combined with standard chemotherapy (nab-paclitaxel and gemcitabine) to shrink locally advanced pancreatic cancer enough that surgery becomes possible. The cancer must have a specific genetic mutation called KRAS G12D for patients to qualify. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with locally advanced pancreatic cancer (not spread to other organs) confirmed by biopsy - Your tumor has the KRAS G12D mutation - You have not had any prior treatment for pancreatic cancer - You are generally in good physical health (able to carry out daily activities) - Your blood counts, liver, and kidney function are within acceptable levels **You may NOT be eligible if...** - Your cancer has spread to other parts of the body - You have had another cancer in the last 5 years (minor skin cancers may be okay) - You have an active autoimmune disease requiring ongoing treatment - You have had a heart attack, stroke, or serious heart condition in the last 6 months - You have poorly controlled blood pressure, active tuberculosis, or active hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.